title: Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: an update.
authors.forename: F
authors.initials: F
authors.lastname: Lefrère
authors.forename: V
authors.initials: V
authors.lastname: Lévy
authors.forename: S
authors.initials: S
authors.lastname: François
authors.forename: R
authors.initials: R
authors.lastname: Delarue
authors.forename: N
authors.initials: N
authors.lastname: Ifrah
authors.forename: H
authors.initials: H
authors.lastname: Tilly
authors.forename: F
authors.initials: F
authors.lastname: Valensi
authors.forename: X
authors.initials: X
authors.lastname: Troussard
authors.forename: B
authors.initials: B
authors.lastname: Varet
authors.forename: O
authors.initials: O
authors.lastname: Hermine
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000037:antagonists & inhibitors; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects / Q000473:pathology*; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D013156:Splenectomy; D013160:Splenic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D004248:DNA (Cytosine-5-)-Methyltransferases; D014740:Vidarabine; C024352:fludarabine